Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Methoxphenidine: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Unity
Add paper
>Unity
m Grammatics
Line 138: Line 138:
==Literature==
==Literature==
* Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
* Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
* * Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620


=References=
=References=

Revision as of 18:08, 6 February 2018

Summary sheet: Methoxphenidine

Template:SubstanceBox/MXP

Methoxphenidine (also known as MXP) is a novel dissociative substance of the diarylethylamine chemical class that produces dissociative and hallucinogenic effects when administered. It is a structural analog of diphenidine and ephenidine.

Methoxphenidine is classified as an NMDA receptor antagonist.[1] Members of this class are primarily used to induce a state known as "dissociative anesthesia" and includes ketamine, PCP, and DXM.

This compound was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury.[2] It has no history of non-medical use before the 2013 UK ban on arylcyclohexylamines, when it and the related compound diphenidine became available on the online research chemicals market in both powder and tablet form.[3] It has been marketed as a replacement for MXE despite many users reporting qualitatively different effects. It is an example of a designer drug specifically chosen to mimic the functional and structural features of commonly used illicit substances and circumvent government regulation.[4][5]

Very little data exists about the pharmacological properties, metabolism, and toxicity of methoxphenidine in humans, and it has a limited history of human usage. A number of fatal and non-fatal overdoses have been linked to the abuse of these compounds.[1]

Chemistry

Generic structure of a piperdine molecule.

Methoxphenidine, or 2-MeO-Diphenidine is a molecule of the diarylethylamine class. It contains a substituted phenethylamine skeleton with an additional phenyl ring bound to Rα. The terminal amino group of the phenethylamine chain is incorporated into a piperidine ring. Hence, methoxphenidine belongs to the piperidine dissociative class of compounds. Methoxphenidine is structurally analogous to Diphenidine, containing an additional 2-methoxy CH3O- substitution.

Pharmacology

Further information: NMDA receptor antagonist

MXP acts as an NMDA receptor antagonist.[6] NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the “k-hole.”

Although it has not been formally studied, the feelings of physical and emotional euphoria which many users report suggests that it may also have action as a dopamine and / or a noradrenaline reuptake inhibitor.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

After effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational MXP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXP has very little history of human usage.

Anecdotal reports from those who have tried this substance that there do not seem to be any negative health effects attributed to simply trying it by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of MXP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of MXP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of MXP all dissociatives will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Canada: As of March 2016, MT-45 and its analogues, one of which being Methoxphenidine, are Schedule I controlled substances.[7] Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
  • China: As of October 2015 MXP is a controlled substance in China.[8]
  • Italy: MXP is banned in Italy according to the Table of Drugs since 2016. [9]
  • Sweden: MXP is also banned in Sweden.[10]
  • United Kingdom: It is illegal to produce, supply, or import this substance under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[11]

See also

Community

Literature

  • Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
  • Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

References

  1. 1.0 1.1 Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
  2. 1,2-diarylethylamines for treatment of neurotoxic injury | https://www.google.com/patents/EP0346791B1
  3. Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers | http://onlinelibrary.wiley.com/doi/10.1002/dta.1800/abstract
  4. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24678061
  5. "Word of mouse": indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25715070
  6. MXP Patent | http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=0346791&KC=&FT=E&locale=en_EP
  7. Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php
  8. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  9. http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
  10. Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/mars/fler-amnen-foreslas-bli-klassade-som-narkotika-eller-halsofarlig-vara/
  11. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted